ePHI flow review
Map every place ePHI moves — APIs, exports, integrations, logs, queues, third-party processors.
Technical-safeguard testing aligned to the HIPAA Security Rule, with explicit ePHI flow review and a BAA-friendly engagement model. Reports your covered-entity partners and HITRUST or SOC 2 + HIPAA auditors accept.
Map every place ePHI moves — APIs, exports, integrations, logs, queues, third-party processors.
Role-based access for clinical, billing, support, and patient roles; tamper-evident audit logs.
Patient and clinician auth, step-up auth for sensitive actions, account-recovery safety.
Patient portals, mobile apps, telehealth, and any place a patient interacts with their record.
FHIR APIs, HL7 interfaces, SMART on FHIR scopes, vendor-to-vendor exchanges.
Backoffice tooling, billing workflows, support-agent access, and the audit trails behind them.
Yes. Findings are mapped to the HIPAA Security Rule technical safeguards (access control, audit controls, integrity, person or entity authentication, transmission security). Reports include the language compliance teams and OCR-prepared documentation expect.
We default to non-production environments with synthetic ePHI. If we must test in production, we agree explicit safe-testing rules, encrypt evidence at rest and in transit, and follow defined retention windows. A signed BAA is in place before any sensitive material is exchanged.
Yes. FHIR APIs, SMART on FHIR scopes, and HL7 interfaces are common surfaces in our healthcare engagements. We test scope and consent boundaries, partner-token isolation, and integration-level access control.
Yes. Reports map cleanly to HITRUST CSF and to SOC 2 with HIPAA-aligned criteria. Cross-walks are documented in the report rather than asked of your team after the fact.
Yes. Covered-entity partners consistently accept our reports as part of vendor risk reviews. The HIPAA-mapping section and explicit scope statement are typically what they look for.
A 30-minute review with our lead pentester. No slides, no pitch — we look at what you have, tell you what we would test first, and give you a fair scope and timeline.